Match each pediatric neurodevelopmental and behavioral clinical vignette with the primary neuropharmacological mechanism of action of the most appropriate targeted pharmacotherapy.
- An 8-year-old boy is brought to the clinic for severe impulsivity and behavioral outbursts at school. He has a history of multiple motor and vocal tics. A non-stimulant medication is selected to manage his hyperactivity because it has also demonstrated efficacy in reducing the severity of his tics.Central alpha-2 adrenergic receptor agonism
- A 16-year-old male requires pharmacological treatment for newly diagnosed attention-deficit/hyperactivity disorder. He has a recent history of cannabis use disorder. His parents explicitly request a non-controlled medication with minimal potential for abuse or diversion.Selective inhibition of the presynaptic norepinephrine transporter
- A 6-year-old boy with autism spectrum disorder exhibits severe, refractory irritability, characterized by extreme tantrums and self-injurious head-banging. A psychotropic agent known for a lower risk of inducing hyperprolactinemia compared to other drugs in its class is initiated.Partial agonism at dopamine D2 and serotonin 5-HT1A receptors
- A 7-year-old boy with attention-deficit/hyperactivity disorder, combined type, struggles with profound inattention leading to academic failure. He has no psychiatric comorbidities and a normal cardiovascular evaluation. The most efficacious, first-line pharmacological agent (a Schedule II controlled substance) is prescribed.Blockade of presynaptic dopamine and norepinephrine reuptake
Answer
The vignettes correctly map to alpha-2 agonism for the patient with tics, selective norepinephrine reuptake inhibition for the patient with substance use risk, partial D2 agonism for the patient with autism and irritability, and DAT/NET blockade for the patient with uncomplicated ADHD.
Each vignette requires a highly specific medication based on comorbidities: tics warrant an alpha-2 agonist, substance use history necessitates a selective norepinephrine reuptake inhibitor, autism with irritability and a desire for lower prolactin risk points to a partial D2 agonist, and uncomplicated severe ADHD requires a stimulant (reuptake blocker of dopamine and norepinephrine).
Step-by-Step Solution
Key Concept
The selection of psychopharmacotherapy in pediatric neurodevelopmental disorders relies on matching specific drug mechanisms (e.g., alpha-2 agonism, specific transporter blockade) to the patient's symptom profile and comorbid conditions.